We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Cards for Cumberland (CPIX) This Earnings Season?
Read MoreHide Full Article
Cumberland Pharmaceuticals Inc. (CPIX - Free Report) is expected to release first-quarter 2019 results soon.
Shares of Cumberland have declined 8.3% year to date against the industry’s growth of 11%.
In the last reported quarter, the company had a positive earnings surprise of 162.50%. Moreover, Cumberland has surpassed earnings estimates in three of the trailing four quarters, the average negative surprise being 0.33%.
Let’s see how things are shaping up prior to the announcement of the upcoming first-quarter 2019 results.
Factors Likely to Impact Q1 Results
Cumberland a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Following the company's acquisition of Vibativfrom Theravance Biopharma in late 2018, its commercial portfolio now includes eight FDA-approved brands.
In 2018, Cumberland submitted an application to the FDA for the approval of its next generation Caldolor product. After a series of interactions with the FDA and amendments to the application, the company was subsequently notified of the product's FDA approval in early 2019. We expect to get updates on the launch of the product during the release of the first-quarter results.
Cumberland continues to advance its pipeline candidates, which includes several new product candidates in phase II studies. The company completed study enrollment for Portaban, its portal hypertension clinical program. Initial review of the data from the study shows ifetroban to be safe and well tolerated, with no unexpected safety findings. Cumberland also continues to advance its Vasculan and Boxaban pipeline prodcuts, with patient enrollment progressing in each of the phase II studies. We expect the company to provide updates on these candidates in the first quarter.
As a result of the Vibativ acquisition, Cumberland inherited a new group of firms, who have licenses to that brand for international markets. The total number of the company's existing international partners now numbers seventeen. The group includes those with rights to Cumberland products in other countries as well as those who have licensed products to the company for the U.S. market. During the first-quarter conference call, the company should provide updates on the capabilities, status and potential of each partner.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show an earnings beat for Cumberland in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Cumberland has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Cumberland Pharmaceuticals Inc. Price and EPS Surprise
Zacks Rank: The company currently has a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Stocks That Warrant a Look
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Inovio Pharmaceuticals, Inc. (INO - Free Report) is scheduled to report first-quarter 2019 results on May 9. The company has an Earnings ESP of +13.79% and a Zacks Rank of 3.
Genmab A/S (GNMSF - Free Report) is scheduled to report first-quarter 2019 results on May 8. The company has an Earnings ESP of +80.95% and a Zacks Rank of 1.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
Image: Bigstock
What's in Cards for Cumberland (CPIX) This Earnings Season?
Cumberland Pharmaceuticals Inc. (CPIX - Free Report) is expected to release first-quarter 2019 results soon.
Shares of Cumberland have declined 8.3% year to date against the industry’s growth of 11%.
In the last reported quarter, the company had a positive earnings surprise of 162.50%. Moreover, Cumberland has surpassed earnings estimates in three of the trailing four quarters, the average negative surprise being 0.33%.
Let’s see how things are shaping up prior to the announcement of the upcoming first-quarter 2019 results.
Factors Likely to Impact Q1 Results
Cumberland a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Following the company's acquisition of Vibativfrom Theravance Biopharma in late 2018, its commercial portfolio now includes eight FDA-approved brands.
In 2018, Cumberland submitted an application to the FDA for the approval of its next generation Caldolor product. After a series of interactions with the FDA and amendments to the application, the company was subsequently notified of the product's FDA approval in early 2019. We expect to get updates on the launch of the product during the release of the first-quarter results.
Cumberland continues to advance its pipeline candidates, which includes several new product candidates in phase II studies. The company completed study enrollment for Portaban, its portal hypertension clinical program. Initial review of the data from the study shows ifetroban to be safe and well tolerated, with no unexpected safety findings. Cumberland also continues to advance its Vasculan and Boxaban pipeline prodcuts, with patient enrollment progressing in each of the phase II studies. We expect the company to provide updates on these candidates in the first quarter.
As a result of the Vibativ acquisition, Cumberland inherited a new group of firms, who have licenses to that brand for international markets. The total number of the company's existing international partners now numbers seventeen. The group includes those with rights to Cumberland products in other countries as well as those who have licensed products to the company for the U.S. market. During the first-quarter conference call, the company should provide updates on the capabilities, status and potential of each partner.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show an earnings beat for Cumberland in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Cumberland has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Cumberland Pharmaceuticals Inc. Price and EPS Surprise
Cumberland Pharmaceuticals Inc. Price and EPS Surprise | Cumberland Pharmaceuticals Inc. Quote
Zacks Rank: The company currently has a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Stocks That Warrant a Look
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Horizon Pharma plc is scheduled to report first-quarter 2019 results on May 8. The company has an Earnings ESP of +25.00% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Inovio Pharmaceuticals, Inc. (INO - Free Report) is scheduled to report first-quarter 2019 results on May 9. The company has an Earnings ESP of +13.79% and a Zacks Rank of 3.
Genmab A/S (GNMSF - Free Report) is scheduled to report first-quarter 2019 results on May 8. The company has an Earnings ESP of +80.95% and a Zacks Rank of 1.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>